Abstract
Schizophrenia and states induced by certain psychotomimetic drugs may share some physiological and phenomenological properties, but they differ in fundamental ways: one is a crippling chronic mental disease, while the others are temporary, pharmacologically-induced states presently being explored as treatments for mental illnesses. Building towards a deeper understanding of these different alterations of normal consciousness, here we compare the changes in neural dynamics induced by LSD and ketamine (in healthy volunteers) against those associated with schizophrenia, as observed in resting-state M/EEG recordings. While both conditions exhibit increased neural signal diversity, our findings reveal that this is accompanied by an increased transfer entropy from the front to the back of the brain in schizophrenia, versus an overall reduction under the two drugs. Furthermore, we show that these effects can be reproduced via different alterations of standard Bayesian inference applied on a computational model based on the predictive processing framework. In particular, the effects observed under the drugs are modelled as a reduction of the precision of the priors, while the effects of schizophrenia correspond to an increased precision of sensory information. These findings shed new light on the similarities and differences between schizophrenia and two psychotomimetic drug states, and have potential implications for the study of consciousness and future mental health treatments.
Introduction
For decades, drugs like LSD and ketamine have been labeled "psychotomimetic" because the hallucinations and ego-dissolution they trigger resemble the symptoms of schizophrenia. Both states are known to increase Lempel-Ziv complexity—a measure of how diverse and non-repeating brain signals are. However, one is a temporary, often therapeutic experience, while the other is a chronic, debilitating disorder. This study seeks the "parting of the ways" between these states, investigating whether the direction of information flow across the brain differs and if these differences can be explained by the Predictive Processing framework.
Methods and Computational Modeling
The researchers combined empirical neuroimaging analysis with computational modeling across three datasets: 64-channel EEG from 29 schizophrenia patients (BSNIP database), and MEG recordings from healthy volunteers under LSD (n=17) and Ketamine (n=19).
Two primary metrics were used:
- Lempel-Ziv (LZ) complexity: To measure signal diversity.
- Transfer Entropy (TE): To measure the directed "flow" of information between brain regions.
To explain the results, the authors built a Bayesian state-space model based on predictive processing. In this model, the brain acts as a "prediction engine" balancing internal expectations (priors) against incoming sensory evidence.
Key Results: Divergent Information Flow
The study confirmed that high neural signal diversity is a hallmark of both states. As shown in the LSD data, signal complexity increases significantly compared to placebo.
However, the Transfer Entropy (TE) revealed a critical divergence:
- Psychedelics (LSD/Ketamine): Showed a widespread decrease in TE between almost all brain regions. The brain essentially stops trusting its internal map (weak priors), letting the world rush in without a structured filter.
- Schizophrenia: Showed a localized increase in TE, specifically flowing from the frontal regions to the occipital (back) regions. Here, the brain turns up the "volume" on sensory signals so high (hyper-precise sensory input) that they overwhelm internal maps.
Discussion and Implications
These findings suggest that while both states involve a relative strengthening of bottom-up sensory influence, the underlying mechanisms are opposites. In the drug state, internal beliefs are relaxed (the REBUS model); in schizophrenia, sensory data is over-weighted.
One important clinical observation was that antipsychotic medication actually decreases signal complexity. Controlling for medication was essential to see the true increase in complexity associated with schizophrenia, suggesting that previous studies may have missed this effect due to patient medication status. Future work will look toward multi-level hierarchical models to better understand complex symptoms like auditory hallucinations, which may involve hyper-precise priors at higher levels of the brain's hierarchy.
Summary updated